NASDAQ:EDIT • US28106W1036
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EDITAS MEDICINE INC (EDIT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Jones Trading | Upgrade | Hold -> Buy |
| 2026-03-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-28 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-12-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-12-13 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2024-12-13 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-12-13 | Stifel | Downgrade | Buy -> Hold |
| 2024-12-13 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-13 | Baird | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-11-05 | Stifel | Maintains | Buy -> Buy |
| 2024-11-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-05 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-23 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-10-23 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-10-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 78.123M 296.36% | 32.314M -58.64% | 40.52M 25.39% | 14.403M -64.45% | 12.896M -10.46% | 11.475M -11.02% | 8.5M -25.93% | 22.78M 168.00% | 71.91M 215.67% | 124.95M 73.76% | 186.15M 48.98% | |
| EBITDA YoY % growth | -163.117M 25.72% | -233.111M -42.91% | N/A 27.58% | -126.983M 24.78% | -140.586M -10.71% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -169.181M 25.12% | -238.92M -41.22% | -99.336M 58.42% | -119.722M -20.52% | -143.591M -19.94% | -164.969M -14.89% | -170.17M -3.15% | -175.78M -3.30% | -167.79M 4.55% | -131.58M 21.58% | -86.7M 34.11% | |
| Operating Margin | -216.56% | -739.37% | -245.15% | -831.23% | -1,113.45% | -1,437.64% | -2,002.00% | -771.64% | -233.33% | -105.31% | -46.58% | |
| EPS YoY % growth | -2.05 36.14% | -2.88 -40.49% | -1.89 34.37% | -1.16 38.73% | -1.02 12.31% | -1.08 -6.81% | -1.03 5.01% | -0.96 6.93% | -0.66 30.85% | -0.17 73.85% | 0.41 335.29% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 67.92% | -0.28 55.45% | -0.32 -14.07% | -0.26 -327.26% |
| Revenue Q2Q % growth | 2.623M -43.69% | 1.483M -58.55% | 2.171M -71.22% | 8.629M -65.12% |
| EBITDA Q2Q % growth | -32.851M 1.62% | -33.649M -54.98% | -34.465M -71.67% | N/A |
| EBIT Q2Q % growth | -30.279M 14.25% | -26.201M -2.90% | -30.83M -25.59% | -24.886M -77.56% |
All data in USD
20 analysts have analysed EDIT and the average price target is 5.32 USD. This implies a price increase of 117.98% is expected in the next year compared to the current price of 2.44.
EDITAS MEDICINE INC (EDIT) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of EDITAS MEDICINE INC (EDIT) is -0.3 USD and the consensus revenue estimate is 2.62M USD.
The consensus rating for EDITAS MEDICINE INC (EDIT) is 74 / 100 . This indicates that analysts generally have a positive outlook on the stock.